Project Grant R21AI188044
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$451K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Arkansas, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,503,349 to the University of Arkansas for Medical Sciences (UAMS) to study the ontogeny (origin) and metabolism of lung alveolar macrophages and their role in tuberculosis (TB) infection. The overarching goal is to understand how the origin and metabolic pathways of these immune cells impact their...
This Project Grant award, totaling $902,964.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant supports research to evaluate mechanisms that restrain or enhance alveolar macrophage (AM) responses to Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis, with the goal of understanding the regulation of early events during MTB infection. The key...
This Project Grant award of $1,011,348 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand how interactions between Mycobacterium tuberculosis (M.TB) and the human alveolar environment, particularly in people living with HIV, impact the early stages of TB infection. The key objectives are to: 1) Determine how M.TB exposure to alveolar lining fluid from people living with...
This Project Grant award of $162,000.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to characterize the role of plasmacytoid dendritic cells (pDCs) in Mycobacterium tuberculosis (MTB) infection. The goal is to identify pDC-specific therapeutic targets that could lead to host-directed therapies for tuberculosis. The 2-year project, running from Jun 1, 2025 to May 31, 2027, will leverage advanced...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $749,414 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University for research on the role of macrophage drug efflux pump MDR1 in Mycobacterium tuberculosis (M.TB) pathogenesis. The primary objectives are to: 1) define the role of MDR1 in M.TB survival in macrophages; 2) determine if HSF1 activation or MDR1 inhibition can shorten M.TB sterilization by TB drugs;...
This federal Project Grant award of $489,500.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the establishment of a novel human lung alveolar epithelial cell organoid model to study Mycobacterium tuberculosis (MTB) infection and host innate immune responses. The primary objectives are to develop a physiologically relevant in vitro platform using human bronchoalveolar lavage fluid (BALF) to...
This Project Grant award of $774,881, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855), supports research to develop pro-apoptotic small molecule host-directed therapies (HDTs) for the treatment of pulmonary tuberculosis (TB). The research aims to utilize these novel HDTs to shorten TB treatment duration, enhance antibiotic penetration, and prevent post-TB lung disease. The project leverages...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,863,501.00 over a 4-year period starting August 1, 2025 to conduct research on the mechanisms of CD4 T cell help to myeloid cells in tuberculosis (TB). The research aims to define how CD4 T cells, through direct cell-cell contact and indirect pathways, activate myeloid cells to control intracellular Mycobacterium...
This Project Grant award of $451,000 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research conducted by The University of Texas Southwestern Medical Center (UT Southwestern) to develop a human lung alveolus-on-a-chip model for studying non-tuberculous mycobacteria (NTM) infections. The goal is to gain insights into NTM pathogenesis, host-pathogen interactions, and identify potential...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $140,256 to Washington University to conduct research on how the tuberculosis (TB) pathogen Mycobacterium tuberculosis (MTB) promotes its survival in neutrophils. The key objectives are to: 1) Investigate how the MTB type VII secretion system (T7SS), specifically the ESX-1 component, affects neutrophil phagosome...